These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

257 related articles for article (PubMed ID: 32001530)

  • 41. Hematopoietic Stem-Cell Transplantation Does Not Improve the Poor Outcome of Children With Hypodiploid Acute Lymphoblastic Leukemia: A Report From Children's Oncology Group.
    McNeer JL; Devidas M; Dai Y; Carroll AJ; Heerema NA; Gastier-Foster JM; Kahwash SB; Borowitz MJ; Wood BL; Larsen E; Maloney KW; Mattano L; Winick NJ; Schultz KR; Hunger SP; Carroll WL; Loh ML; Raetz EA
    J Clin Oncol; 2019 Apr; 37(10):780-789. PubMed ID: 30742559
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Intrachromosomal amplification of chromosome 21 is associated with inferior outcomes in children with acute lymphoblastic leukemia treated in contemporary standard-risk children's oncology group studies: a report from the children's oncology group.
    Heerema NA; Carroll AJ; Devidas M; Loh ML; Borowitz MJ; Gastier-Foster JM; Larsen EC; Mattano LA; Maloney KW; Willman CL; Wood BL; Winick NJ; Carroll WL; Hunger SP; Raetz EA
    J Clin Oncol; 2013 Sep; 31(27):3397-402. PubMed ID: 23940221
    [TBL] [Abstract][Full Text] [Related]  

  • 43. [Clinical importance of minimal residual disease testing in the therapy of childhood B-cell acute lymphoblastic leukemia].
    Ye QD; Gu LJ; Tang JY; Xue HL; Chen J; Pan C; Chen J; Dong L; Zhou M; Jiang LM
    Zhongguo Dang Dai Er Ke Za Zhi; 2008 Jun; 10(3):333-6. PubMed ID: 18554462
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Importance of minimal residual disease testing during the second year of therapy for children with acute lymphoblastic leukemia.
    Marshall GM; Haber M; Kwan E; Zhu L; Ferrara D; Xue C; Brisco MJ; Sykes PJ; Morley A; Webster B; Dalla Pozza L; Waters K; Norris MD
    J Clin Oncol; 2003 Feb; 21(4):704-9. PubMed ID: 12586809
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Efficacy and toxicity of high-risk therapy of the Dutch Childhood Oncology Group in childhood acute lymphoblastic leukemia.
    van Binsbergen AL; de Haas V; van der Velden VHJ; de Groot-Kruseman HA; Fiocco MF; Pieters R
    Pediatr Blood Cancer; 2022 Feb; 69(2):e29387. PubMed ID: 34648216
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Obesity is associated with residual leukemia following induction therapy for childhood B-precursor acute lymphoblastic leukemia.
    Orgel E; Tucci J; Alhushki W; Malvar J; Sposto R; Fu CH; Freyer DR; Abdel-Azim H; Mittelman SD
    Blood; 2014 Dec; 124(26):3932-8. PubMed ID: 25349177
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Allogeneic hematopoietic cell transplantation outcomes for children with B-precursor acute lymphoblastic leukemia and early or late BM relapse.
    Beck JC; Cao Q; Trotz B; Smith AR; Weigel BJ; Verneris MR; Burke MJ
    Bone Marrow Transplant; 2011 Jul; 46(7):950-5. PubMed ID: 20856210
    [TBL] [Abstract][Full Text] [Related]  

  • 48. ETV6/RUNX1-positive childhood acute lymphoblastic leukemia in China: excellent prognosis with improved BFM protocol.
    Wang Y; Zeng HM; Zhang LP
    Ital J Pediatr; 2018 Aug; 44(1):94. PubMed ID: 30115129
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Outcome in Children With Standard-Risk B-Cell Acute Lymphoblastic Leukemia: Results of Children's Oncology Group Trial AALL0331.
    Maloney KW; Devidas M; Wang C; Mattano LA; Friedmann AM; Buckley P; Borowitz MJ; Carroll AJ; Gastier-Foster JM; Heerema NA; Kadan-Lottick N; Loh ML; Matloub YH; Marshall DT; Stork LC; Raetz EA; Wood B; Hunger SP; Carroll WL; Winick NJ
    J Clin Oncol; 2020 Feb; 38(6):602-612. PubMed ID: 31825704
    [TBL] [Abstract][Full Text] [Related]  

  • 50. The UK experience in treating relapsed childhood acute lymphoblastic leukaemia: a report on the medical research council UKALLR1 study.
    Lawson SE; Harrison G; Richards S; Oakhill A; Stevens R; Eden OB; Darbyshire PJ
    Br J Haematol; 2000 Mar; 108(3):531-43. PubMed ID: 10759711
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Novel multiagent chemotherapy for bone marrow relapse of pediatric acute lymphoblastic leukemia.
    Leahey AM; Bunin NJ; Belasco JB; Meek R; Scher C; Lange BJ
    Med Pediatr Oncol; 2000 May; 34(5):313-8. PubMed ID: 10797352
    [TBL] [Abstract][Full Text] [Related]  

  • 52. MRD at the end of induction and EFS in T-cell lymphoblastic lymphoma: Children's Oncology Group trial AALL1231.
    Hayashi RJ; Hermiston ML; Wood BL; Teachey DT; Devidas M; Chen Z; Annett RD; Asselin BL; August K; Cho S; Dunsmore KP; Freedman JL; Galardy PJ; Harker-Murray P; Horton TM; Jaju A; Lam A; Messinger YH; Miles RR; Okada M; Patel S; Schafer ES; Schechter T; Shimano KA; Singh N; Steele A; Sulis ML; Vargas SL; Winter SS; Wood C; Zweidler-McKay PA; Loh ML; Hunger SP; Raetz EA; Bollard CM; Allen CE
    Blood; 2024 May; 143(20):2053-2058. PubMed ID: 38457359
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Impact of minimal residual disease status in patients with relapsed/refractory acute lymphoblastic leukemia treated with inotuzumab ozogamicin in the phase III INO-VATE trial.
    Jabbour E; Gökbuget N; Advani A; Stelljes M; Stock W; Liedtke M; Martinelli G; O'Brien S; Wang T; Laird AD; Vandendries E; Neuhof A; Nguyen K; Dakappagari N; DeAngelo DJ; Kantarjian H
    Leuk Res; 2020 Jan; 88():106283. PubMed ID: 31790983
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Persistent MRD before and after allogeneic BMT predicts relapse in children with acute lymphoblastic leukaemia.
    Sutton R; Shaw PJ; Venn NC; Law T; Dissanayake A; Kilo T; Haber M; Norris MD; Fraser C; Alvaro F; Revesz T; Trahair TN; Dalla-Pozza L; Marshall GM; O'Brien TA
    Br J Haematol; 2015 Feb; 168(3):395-404. PubMed ID: 25312094
    [TBL] [Abstract][Full Text] [Related]  

  • 55. [The Factors Related to Treatment Failure in Children with Acute Lymphoblastic Leukemia].
    Gao W; Jiang MY; Gao L; Lu J; Xiao PF; He HL; Wang Y; Pan J; Ling J; Sun YN; Hu SY
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2021 Jun; 29(3):661-668. PubMed ID: 34105454
    [TBL] [Abstract][Full Text] [Related]  

  • 56. [Clinical and Prognostic analysis of 43 Children with Mature B-cell Non-Hodgkin's Lymphoma/Acute Lymphoblastic Leukemia].
    Guo J; Zhu YP; Gao J; Li Q; Jia CS; Zhou CY; Guo X
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2016 Feb; 24(1):72-9. PubMed ID: 26913397
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Clinical significance of minimal residual disease in childhood acute lymphoblastic leukemia after first relapse.
    Coustan-Smith E; Gajjar A; Hijiya N; Razzouk BI; Ribeiro RC; Rivera GK; Rubnitz JE; Sandlund JT; Andreansky M; Hancock ML; Pui CH; Campana D
    Leukemia; 2004 Mar; 18(3):499-504. PubMed ID: 14981525
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Prognostic impact of minimal residual disease at the end of consolidation in NCI standard-risk B-lymphoblastic leukemia: A report from the Children's Oncology Group.
    Rau RE; Dai Y; Devidas M; Rabin KR; Zweidler-McKay P; Angiolillo A; Schore RJ; Burke MJ; Salzer WL; Heerema NA; Carroll AJ; Winick NJ; Hunger SP; Raetz EA; Loh ML; Wood BL; Borowitz MJ
    Pediatr Blood Cancer; 2021 Apr; 68(4):e28929. PubMed ID: 33559396
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Treatment of high-risk Philadelphia chromosome-negative acute lymphoblastic leukemia in adolescents and adults according to early cytologic response and minimal residual disease after consolidation assessed by flow cytometry: final results of the PETHEMA ALL-AR-03 trial.
    Ribera JM; Oriol A; Morgades M; Montesinos P; Sarrà J; González-Campos J; Brunet S; Tormo M; Fernández-Abellán P; Guàrdia R; Bernal MT; Esteve J; Barba P; Moreno MJ; Bermúdez A; Cladera A; Escoda L; García-Boyero R; Del Potro E; Bergua J; Amigo ML; Grande C; Rabuñal MJ; Hernández-Rivas JM; Feliu E
    J Clin Oncol; 2014 May; 32(15):1595-604. PubMed ID: 24752047
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Prognostic significance of ETP phenotype and minimal residual disease in T-ALL: a Children's Oncology Group study.
    Wood BL; Devidas M; Summers RJ; Chen Z; Asselin B; Rabin KR; Zweidler-McKay PA; Winick NJ; Borowitz MJ; Carroll WL; Raetz EA; Loh ML; Hunger SP; Dunsmore KP; Teachey DT; Winter SS
    Blood; 2023 Dec; 142(24):2069-2078. PubMed ID: 37556734
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.